1.	Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 0 to 18 Sponsor: NCI Protocol IDs: CCG-3891
2.	Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97) Phase: Phase III Type: Treatment Status: Completed Age: no greater than 60 Sponsor: NCI Protocol IDs: NU-93B1, NCI-T93-0058D, T93-0058
3.	Phase III Randomized Study of MOAB-Purged vs Unpurged Autologous Bone Marrow Following Myeloablative BU/CTX in Adult Acute Myeloid Leukemia in Second Complete Remission (Summary Last Modified 04/2000) Phase: Phase III Type: Treatment Status: Closed Age: 65 and under Sponsor: Other Protocol IDs: PCI-9404, NCI-V94-0494
4.	Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: under 65 Sponsor: Protocol IDs: MRC-LEUK-MYEL-VII, EU-94030, NCT00002599
5.	Phase III Randomized Study of ARA-C/DNR vs DHAD/VP-16 Induction Therapy Followed by ARA-C/DNR Consolidation Therapy in Older Patients with Previously Untreated Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 56 and over Sponsor: NCI Protocol IDs: SWOG-9333
6.	Phase III Randomized Study of Rescue with CD34+ Selected vs Unselected Autologous PBSC Following High-Dose BU/CTX for Multiple Myeloma (Summary Last Modified 03/97) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CP-0060-002, NCI-V95-0712
7.	Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 96-015, P30CA008748, MSKCC-96015A1, NCI-V96-0881, NCT00002766
8.	Phase III Randomized Study of Liposomal Amphotericin B with or without Sargramostim in Patients with Invasive Fungal Infections Entered into Protocols MRC-LEUK-AML11, AML12, or UKALLXII (Summary Last Modified 05/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Supportive care Status: Closed Age: 15 and over Sponsor: Protocol IDs: MRC-LEUK-IFI, EU-97030, NCT00003315
9.	Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Phase: Phase III Type: Treatment Status: Completed Age: Under 50 Sponsor: NCI, Other Protocol IDs: CDR0000067157, COG-D9803, CCG-D9803, POG-D9803, IRS-D9803, D9803, NCT00003958
10.	Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034
11.	Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000068406, RTOG-9901, NCI-P00-0177, NCT00008398
12.	Phase III Randomized Study of Cyclophosphamide, Prednisone, and Vincristine Followed By Immunotherapy With Keyhole Limpet Hemocyanin With or Without Recombinant Autologous Tumor-Derived Immunoglobulin Idiotype and Adjuvant Sargramostim (GM-CSF) in Patients With Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENITOPE-G2000-03, CUMC-0101-142, UCLA-0010061, NCT00017290
13.	Phase III VMCP plus VBAP for Previously Untreated Stage I/II/III Multiple Myeloma with Hemi-body Radiotherapy plus VCR/PRED vs VMCP for Responders Phase: Phase III Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-8229/30, SWOG-8230
14.	Phase III Comparison of Autologous BMT vs Second Consolidation with HDARA-C/DNM vs Allogeneic BMT Following Induction with DNM/ARA-C with vs without GM-CSF and Consolidation with HDARA-C/AMSA in Patients with Acute Myelogenous Leukemia (Summary Last Modified 01/91) Phase: Phase III Type: Treatment Status: Closed Age: 10 to 60 Sponsor: Protocol IDs: EORTC-06863
15.	A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) Phase: Phase III Type: Treatment Status: Completed Age: 45 to 60 Sponsor: Other Protocol IDs: EORTC-06864, NCT01324063
16.	Phase III Randomized Double-Blind Placebo-Controlled Evaluation of Recombinant GM-CSF in Patients Undergoing Autologous or Syngeneic Bone Marrow Therapy (Summary Last Modified 02/89) Phase: Phase III Type: Treatment Status: Closed Age: over 15 to less than 65 Sponsor: Protocol IDs: MSKCC-88108, NCI-V88-0644
17.	Phase III Randomized Double-Blind Placebo-Controlled Evaluation of Recombinant GM-CSF in Patients Undergoing Autologous or Syngeneic Bone Marrow Therapy (Summary Last Modified 12/89) Phase: Phase III Type: Treatment Status: Closed Age: over 15 to less than 65 Sponsor: Protocol IDs: GUMC-14088, NCI-V89-0065
18.	Phase III Randomized Comparison of Radiotherapy plus Induction Chemotherapy Using VP-16/CDDP with vs without GM-CSF and of Maintenance with IFN-A vs No Maintenance in Patients with Limited Stage Small Cell Lung Cancer (Summary Last Modified 07/97) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-8812
19.	Phase III Randomized Study of GM-CSF vs Placebo in Elderly Patients with AML Undergoing Remission Induction Therapy with DNR/ARA-C and of ARA-C vs ARA-C/DHAD as Intensification Therapy Phase: Phase III Type: Treatment Status: Closed Age: 60 and over Sponsor: NCI Protocol IDs: CLB-8923, CALGB-8923
20.	Phase III Randomized Double-Blind Study of Intensive Chemotherapy with ARA-C/CACP/VP-16 plus GM-CSF vs Placebo in Patients with Relapsing or Refractory Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 11/90) Phase: Phase III Type: Treatment Status: Closed Age: 15 and over Sponsor: Protocol IDs: AECM-8903071, NCI-V89-0161
21.	Phase III Randomized Double-Blind Study of Intensive Chemotherapy with ARA-C/CACP/VP-16 plus GM-CSF vs Placebo in Patients with Relapsing or Refractory Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 12/89) Phase: Phase III Type: Treatment Status: Closed Age: 15 and over Sponsor: Protocol IDs: UW-C89-049-05, NCI-V89-0252
22.	Phase III Randomized Double-Blind Trial of GM-CSF vs Placebo Following DNM/ARA-C Induction and High-Dose ARA-C Consolidation in Elderly Patients with AML Phase: Phase III Type: Treatment Status: Completed Age: 55 to 70 Sponsor: NCI Protocol IDs: EST-1490
23.	Phase III Randomized Study of GM-CSF as an Adjunct to DNR/ARA-C Induction in Elderly Patients with AML and of Maintenance Therapy with Low-Dose ARA-C vs No Maintenance Therapy (Summary Last Modified 09/90) Phase: Phase III Type: Treatment Status: Closed Age: 61 and over Sponsor: Protocol IDs: EORTC-06892
24.	Phase III Randomized Double-Blind Study of Intensive Chemotherapy with ARA-C/CDDP/VP-16 plus GM-CSF vs Placebo in Patients with Relapsing or Refractory Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 10/90) Phase: Phase III Type: Treatment Status: Closed Age: 15 and over Sponsor: Protocol IDs: MAOP-3189, NCI-V90-0118
25.	Phase III Randomized Double-Blind Study of Intensive Chemotherapy with ARA-C/CDDP/VP-16 plus GM-CSF vs Placebo in Patients with Relapsing or Refractory Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 10/90) Phase: Phase III Type: Treatment Status: Completed Age: 15 and over Sponsor: Protocol IDs: MSKCC-90085, NCI-V90-0148